Evidence map›Paper›PMID 35530849›Full record

ArticleCureus2022

A Normalized Real-Life Glucose Profile After Diet-Induced Remission of Type 2 Diabetes: A Pilot Trial.

Stefanie J Haschka, Christina Gar, Anne L Potzel, Vanessa Sacco, Stefanie Kern-Matschilles, Irina Benz, Cornelia Then, Jochen Seissler, Andreas Lechner

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Stefanie J HaschkaDiabetes Research Group, Ludwig-Maximilians-Universität (LMU) Klinikum, Munich, DEU.
Christina GarDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Anne L PotzelDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Vanessa SaccoDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Stefanie Kern-MatschillesDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Irina BenzDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Cornelia ThenDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Jochen SeisslerDiabetes Research Group, Ludwig-Maximilians-Universität (LMU) Klinikum, Munich, DEU.
Andreas LechnerDiabetes and Endocrinology, German Center for Diabetes Research, Neuherberg, DEU.
Klinikum rechts der Isar · DELudwig-Maximilians-Universität München · DEHelmholtz Zentrum München · DELMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/objective Type 2 diabetes related to metabolic syndrome is often partially reversible after weight loss. We conducted a pilot trial on whether complete remission to the point of a normalized real-life glucose profile, measured by continuous subcutaneous monitoring, can be achieved. Methods We conducted a mono-center, single-arm intervention trial between January 20, 2020, and January 12, 2021, in Munich, Germany. Ten participants had type 2 diabetes related to metabolic syndrome for a maximum of six years. They received a six-month lifestyle intervention including up to three months of a very-low-calorie formula diet, followed by stepwise food reintroduction and regular behavioral lifestyle counseling. The primary outcome was the status of glucose control at the end of the intervention. Complete remission was defined as normalization of the real-life glucose profile without glucose-lowering medication over at least five days. We measured anthropometric and biochemical parameters, body fat distribution by MRI, and insulin secretory reserve by an arginine stimulation test. Results Seven participants completed the trial, one reached complete remission, three achieved partial remission, and three displayed improved glucose control still in the diabetic range. A reduction of median glycosylated hemoglobin by -10 mmol/mol (-22.0 to -5.0; p = 0.016) co-occurred with weight loss of -6.4 kg (-14.2 to -3.5; p = 0.031). The insulin secretory reserve remained unchanged. Conclusions Complete remission of type 2 diabetes related to metabolic syndrome to the point of a normalized real-life glucose profile is possible through lifestyle intervention. Full intervention success remains challenging even with intensive counseling and support.

Indexed as

diabetes mellitus type 2diabetes remissionintermittently scanned continuous glucose monitoringlifestyle interventionmetabolic syndrome

Identifiers

PMID35530849
PMCPMC9076033
OpenAlexW4226212792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.